Population Physiologically‐Based Pharmacokinetic Modeling to Determine Ontogeny: A Quantitative Clinical Pharmacology Example in Pediatric Rare Disease [PDF]
CPT: Pharmacometrics & Systems PharmacologyPediatric physiologically‐based pharmacokinetic (PBPK) modelling plays an increasing role in selecting doses in children and addressing clinical pharmacology questions.
Yumi Cleary +4 more
doaj +2 more sources
Integrating Population Approaches With Physiologically Based Pharmacokinetic Models: A Novel Framework for Parameter Estimation [PDF]
CPT: Pharmacometrics & Systems PharmacologyPhysiologically Based Pharmacokinetic (PBPK) modeling is a powerful tool in drug development that integrates drug‐specific information with physiological parameters to predict drug concentrations.
Donato Teutonico +3 more
doaj +2 more sources
Physiologically‐Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges [PDF]
CPT: Pharmacometrics & Systems PharmacologyPediatric extrapolation strategies issued by health authorities have streamlined pediatric drug development and reduced the unnecessary burden of conducting pediatric clinical studies. In line with these strategies, physiologically based pharmacokinetic (
James W. T. Yates +26 more
doaj +2 more sources
Predictive modelling and simulation for taming the chance and luck in biologics drug discovery [PDF]
Proceedings of the Estonian Academy of Sciences, 2023 Three Pillars of Survival paradigm in the pharmaceutical drug discovery stipulates that a drug candidate is more likely to reach Phase III if it meets the following criteria: 1) it reaches the required tissue compartment, 2) engages the desired target, 3)
Armin Sepp
doaj +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2022 The phase distribution model, proposed by Atkinson and Begg in 1990, has been widely used for predicting breastmilk‐to‐plasma drug concentration ratio. However, misrepresentations of the equations have been noted in recent publications.
Mian Zhang +5 more
doaj +1 more source
The emerging role of physiologically-based pharmacokinetic/biopharmaceutics modeling in formulation development [PDF]
Arhiv za farmaciju, 2021 Computer-based (in silico) modeling & simulation tools have been embraced in different fields of pharmaceutics for a variety of applications. Among these, physiologically-based pharmacokinetic/biopharmaceutics modeling (PBPK/PBBM) emerged as a ...
Cvijić Sandra +3 more
doaj +1 more source
Review of the pharmacokinetics of nanodrugs
Nanotechnology Reviews, 2023 Nanodrug delivery systems (NDDSs) are a hotspot of new drug delivery systems with great development potential. They provide new approaches to fighting against diseases.
Shao Xiaotong +4 more
doaj +1 more source
Population variability in animal health: Influence on dose-exposure-response relationships: Part II: Modelling and simulation [PDF]
, 2018 During the 2017 Biennial meeting, the American Academy of Veterinary Pharmacology and Therapeutics hosted a 1‐day session on the influence of population variability on dose‐exposure‐response relationships. In Part I, we highlighted some of the sources of
Bailey +40 more
core +7 more sources
Lost in modelling and simulation?
ADMET and DMPK, 2021 Over the past few decades, physiologically-based pharmacokinetic modelling (PBPK) has been anticipated to be a powerful tool to improve the productivity of drug discovery and development.
Kiyohiko Sugano
doaj +1 more source
Pharmaceutics, 2020 The application of in silico modeling to predict the in vivo outcome of an oral drug product is gaining a lot of interest. Fully relying on these models as a surrogate tool requires continuous optimization and validation.
Marival Bermejo +7 more
doaj +1 more source